Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Iyoke CAUG. Burden of gynaecological cancers in developing countries. World J Obstet Gynecol. 2013;2(1):1–7.
   Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–79.
   PubMed Web of Science ®Google Scholar
• Howley PM, Lowy DR. Papillomaviruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins 2007; p. 2300–2354.
   Google Scholar
• de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10.
   PubMed Web of Science ®Google Scholar
• Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–F70.
   PubMedGoogle Scholar
• Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215–222.
   PubMed Web of Science ®Google Scholar
• McBride AA. Replication and partitioning of papillomavirus genomes. Adv Virus Res. 2008;72:155–205.
   PubMed Web of Science ®Google Scholar
• Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics. 2009;2:32.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr. HPV DNA testing for cervical cancer screening. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S239–S246.
   Google Scholar
• Wentzensen N. von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23(4):315–330.
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M, Reuschenbach M, Schmidt D, et al. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics. 2012;9(2):149–163.
   PubMed Web of Science ®Google Scholar
• de Freitas AC, Coimbra EC, Leitao Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochim Biophys Acta. 2014;1845(2):91–103.
   PubMed Web of Science ®Google Scholar
• Lomnytska M, Souchelnytskyi S. Markers of breast and gynecological malignancies: the clinical approach of proteomics-based studies. Proteomics Clin Appl. 2007;1(9):1090–1101.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, De Marco F, Perluigi M. Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer. Expert Rev Proteomics. 2013;10(5):461–472.
   PubMed Web of Science ®Google Scholar
• Breuer EK, Murph MM. The role of proteomics in the diagnosis and treatment of women’s cancers: current trends in technology and future opportunities. Int J Proteomics. 2011;2011:1–17.
   PubMedGoogle Scholar
• Ueda Y, Enomoto T, Kimura T, et al. Serum biomarkers for early detection of gynecologic cancers. Cancers. 2010;2(2):1312–1327.
   PubMedGoogle Scholar
• Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol. 2011;23(1):3–7.
   PubMed Web of Science ®Google Scholar
• Zegels G, Van Raemdonck GA, Tjalma WA, et al. Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci. 2010;8:63.
   PubMed Web of Science ®Google Scholar
• Yim EK, Park JS. Role of proteomics in translational research in cervical cancer. Expert Rev Proteomics. 2006;3(1):21–36.
   PubMed Web of Science ®Google Scholar
• Lin LH, Chang SJ, Hu RY, et al. Biomarker discovery for neuroendocrine cervical cancer. Electrophoresis. 2014;35(14):2039–2045.
   PubMed Web of Science ®Google Scholar
• Zhao Q, He Y, Wang XL, et al. Differentially expressed proteins among normal cervix, cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Clini Transl Oncol. 2015;17(8):620–631.
   PubMed Web of Science ®Google Scholar
• Arnouk H, Merkley MA, Podolsky RH, et al. Characterization of molecular markers indicative of cervical cancer progression. Proteomics Clin Appl. 2009;3(5):516–527.
   PubMed Web of Science ®Google Scholar
• Fukushima C, Murakami A, Yoshitomi K, et al. Comparative proteomic profiling in squamous cell carcinoma of the uterine cervix. Proteomics Clin Appl. 2011;5(3–4):133–140.
   PubMed Web of Science ®Google Scholar
• Lomnytska MI, Becker S, Hellman K, et al. Diagnostic protein marker patterns in squamous cervical cancer. Proteomics Clin Appl. 2010;4(1):17–31.
   PubMed Web of Science ®Google Scholar
• Hwang YJ, Lee SP, Kim SY, et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J. 2009;50(3):399–406.
   PubMed Web of Science ®Google Scholar
• Escobar-Hoyos LF, Yang J, Zhu J, et al. Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol. 2014;27(4):621–630.
   PubMed Web of Science ®Google Scholar
• Wang W, Jia HL, Huang JM, et al. Identification of biomarkers for lymph node metastasis in early-stage cervical cancer by tissue-based proteomics. Br J Cancer. 2014;110(7):1748–1758.
   PubMed Web of Science ®Google Scholar
• Yu LR, Lv JQ, Jin LY, et al. Over-expression of protein kinase Cisoforms (alpha, delta, theta and zeta) in squamous cervical cancer. Neoplasma. 2011;58(6):491–498.
   PubMed Web of Science ®Google Scholar
• Choi YP, Kang S, Hong S, et al. Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics. 2005;5(6):1481–1493.
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M, Handa K, Yugawa T, et al. HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene. 2007;26(21):2988–2996.
   PubMed Web of Science ®Google Scholar
• Zhu X, Lv J, Yu L, et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol. 2009;112(1):248–256.
   PubMed Web of Science ®Google Scholar
• Song JY, Bae HS, Koo do H, et al. Candidates for tumor markers of cervical cancer discovered by proteomic analysis. J Korean Med Sci. 2012;27(12):1479–1485.
   PubMed Web of Science ®Google Scholar
• Bae SM, Lee CH, Cho YL, et al. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol. 2005;99(1):26–35.
   PubMed Web of Science ®Google Scholar
• Looi ML, Karsani SA, Rahman MA, et al. Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci. 2009;34(6):917–925.
   PubMed Web of Science ®Google Scholar
• Lin YW, Lai HC, Lin CY, et al. Plasma proteomic profiling for detecting and differentiating in situ and invasive carcinomas of the uterine cervix. Int J Gynecol Cancer. 2006;16(3):1216–1224.
   PubMed Web of Science ®Google Scholar
• Guo X, Hao Y, Kamilijiang M, et al. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and ingenuity pathway analysis. Tumour Biol. 2015;36(3):1711–1720.
   PubMed Web of Science ®Google Scholar
• Liu C, Pan C, Shen J, et al. Discrimination analysis of mass spectrometry proteomics for cervical cancer detection. Med Oncol. 2011;28(Suppl 1):S553–S559.
   Google Scholar
• Lokamani I, Looi ML, Md Ali SA, et al. Gelsolin and ceruloplasmin as potential predictive biomarkers for cervical cancer by 2D-DIGE proteomics analysis. Pathol Oncol Res. 2014;20(1):119–129.
   PubMed Web of Science ®Google Scholar
• Patil A, Bhat S, Pai KM, et al. Ultra-sensitive high performance liquid chromatography-laser-induced fluorescence based proteomics for clinical applications. J Proteomics. 2015;127(Pt A):202–210.
   PubMedGoogle Scholar
• Boichenko AP, Govorukhina N, Klip HG, et al. A panel of regulated proteins in serum from patients with cervical intraepithelial neoplasia and cervical cancer. J Proteome Res. 2014;13(11):4995–5007.
   PubMed Web of Science ®Google Scholar
• Rader JS, Malone JP, Gross J, et al. A unified sample preparation protocol for proteomic and genomic profiling of cervical swabs to identify biomarkers for cervical cancer screening. Proteomics Clin Appl. 2008;2(12):1658–1669.
   PubMed Web of Science ®Google Scholar
• Wong YF, Cheung TH, Lo KW, et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 2004;211(2):227–234.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wu SL, Meyer JL, et al. Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry. J Proteome Res. 2007;6(11):4256–4268.
   PubMed Web of Science ®Google Scholar
• Canham M, Charsou C, Stewart J, et al. Increased cycling cell numbers and stem cell associated proteins as potential biomarkers for high grade human papillomavirus+ve pre-neoplastic cervical disease. Plos One. 2014;9(12):e115379.
   PubMed Web of Science ®Google Scholar
• Papachristou EK, Roumeliotis TI, Chrysagi A, et al. The shotgun proteomic study of the human ThinPrep cervical smear using iTRAQ mass-tagging and 2D LC-FT-Orbitrap-MS: the detection of the human papillomavirus at the protein level. J Proteome Res. 2013;12(5):2078–2089.
   PubMed Web of Science ®Google Scholar
• Van Raemdonck GA, Tjalma WA, Coen EP, et al. Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. Plos One. 2014;9(9):e106488.
   PubMed Web of Science ®Google Scholar
• Boylan KL, Afiuni-Zadeh S, Geller MA, et al. A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. Clin Proteomics. 2014;11(1):30.
   PubMedGoogle Scholar
• Panicker G, Ye Y, Wang D, et al. Characterization of the human cervical mucous proteome. Clin Proteomics. 2010;6(1–2):18–28.
   PubMedGoogle Scholar
• Yim EK, Lee KH, Kim CJ, et al. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int J Gynecolog Cancer. 2006;16(2):690–697.
   PubMed Web of Science ®Google Scholar
• Yim EK, Lee SB, Lee KH, et al. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. Int J Gynecolog Cancer. 2006;16(3):1321–1329.
   PubMed Web of Science ®Google Scholar
• Yim EK, Bae JS, Lee SB, et al. Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment. Cancer Res Treat. 2004;36(6):395–399.
   PubMedGoogle Scholar
• Lee KH, Yim EK, Kim CJ, et al. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005;98(1):45–53.
   PubMed Web of Science ®Google Scholar
• Memin E, Hoque M, Jain MR, et al. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation. Cancer Res. 2014;74(2):552–562.
   PubMed Web of Science ®Google Scholar
• Yue Q, Feng L, Cao B, et al. Proteomic analysis revealed the important role of vimentin in human cervical carcinoma HeLa cells treated with gambogic acid. Mol Cell Proteomics. 2015;15(1):26–44.
   Web of Science ®Google Scholar
• Pan TL, Hung YC, Wang PW, et al. Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics. 2010;10(5):914–929.
   PubMed Web of Science ®Google Scholar
• Pan TL, Wang PW, Hung YC, et al. Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. Proteomics. 2013;13(23–24):3411–3423.
   PubMed Web of Science ®Google Scholar
• Liu Q, Peng YB, Qi LW, et al. The cytotoxicity mechanism of 6-shogaol-treated HeLa human cervical cancer cells revealed by label-free shotgun proteomics and bioinformatics analysis. Evid Based Complement Alternat Med. 2012;278652:2012.
   Google Scholar
• Santos RC, Salvador JA, Marin S, et al. Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg Med Chem. 2009;17(17):6241–6250.
   PubMed Web of Science ®Google Scholar
• Xu T, Pang Q, Zhou D, et al. Proteomic investigation into betulinic acid-induced apoptosis of human cervical cancer HeLa cells. Plos One. 2014;9(8):e105768.
   PubMedGoogle Scholar
• Deguchi A. Curcumin targets in inflammation and cancer. Endocr Metab Immune Disord Drug Targets. 2015;15(2):88–96.
   PubMed Web of Science ®Google Scholar
• Madden K, Flowers L, Salani R, et al. Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot Essent Fatty Acids. 2009;80(1):9–18.
   PubMed Web of Science ®Google Scholar
• Huang TC, Chen JY. Proteomic analysis reveals that pardaxin triggers apoptotic signaling pathways in human cervical carcinoma HeLa cells: cross talk among the UPR, c-Jun and ROS. Carcinogenesis. 2013;34(8):1833–1842.
   PubMed Web of Science ®Google Scholar
• Shen L, Liu Q, Ni J, et al. A proteomic investigation into the human cervical cancer cell line HeLa treated with dicitratoytterbium (III) complex. Chem Biol Interact. 2009;181(3):455–462.
   PubMed Web of Science ®Google Scholar
• Shen L, Lan Z, Sun X, et al. Proteomic analysis of lanthanum citrate-induced apoptosis in human cervical carcinoma SiHa cells. Biometals. 2010;23(6):1179–1189.
   PubMed Web of Science ®Google Scholar
• Yim EK, Lee KH, Namkoong SE, et al. Proteomic analysis of ursolic acid-induced apoptosis in cervical carcinoma cells. Cancer Lett. 2006;235(2):209–220.
   PubMed Web of Science ®Google Scholar
• Masters JR. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002;2(4):315–319.
   PubMed Web of Science ®Google Scholar
• Lucey BP, Nelson-Rees WA, Hutchins GM. Henrietta Lacks, HeLa cells, and cell culture contamination. Arch Pathol Lab Med. 2009;133(9):1463–1467.
   PubMed Web of Science ®Google Scholar
• Pimenta JM, Galindo C, Jenkins D, et al. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer. 2013;13:553.
   PubMed Web of Science ®Google Scholar
• Liu H, Han Y, Mi R, et al. Identification of cervical cancer proteins associated with treatment with paclitaxel and cisplatin in patients. Int J Gynecol Cancer. 2011;21(8):1452–1457.
   PubMed Web of Science ®Google Scholar
• Zou S, Shen Q, Hua Y, et al. Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer. Reprod Sci. 2013;20(11):1356–1364.
   PubMed Web of Science ®Google Scholar
• Zhu H, Pei HP, Zeng S, et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma. J Proteome Res. 2009;8(8):3969–3976.
   PubMed Web of Science ®Google Scholar
• Serrano-Olvera A, Cetina L, Coronel J, et al. Emerging drugs for the treatment of cervical cancer. Expert Opin Emerg Drugs. 2015;20(2):165–182.
   PubMed Web of Science ®Google Scholar
• Maneo A, Chiari S, Bonazzi C, et al. Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol. 2008;111(3):438–443.
   PubMed Web of Science ®Google Scholar
• Rahangdale L, Lippmann QK, Garcia K, et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol. 2014;210(4):314 e311–318.
   Google Scholar
• Dakna M, Harris K, Kalousis A, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010;11:594.
   PubMed Web of Science ®Google Scholar
• Hubbard RA. Human papillomavirus testing methods. Arch Pathol Lab Med. 2003;127(8):940–945.
   PubMed Web of Science ®Google Scholar
• Vachani A, Pass HI, Rom WN, et al. Validation of a multiprotein plasma classifier to identify benign lung nodules. J Thoracic Oncol. 2015;10(4):629–637.
   PubMed Web of Science ®Google Scholar
• Sun H, Chen C, Lian B, et al. Identification of HPV integration and gene mutation in HeLa cell line by integrated analysis of RNA-Seq and MS/MS data. J Proteome Res. 2015;14(4):1678–1686.
   PubMed Web of Science ®Google Scholar
• Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. Plos One. 2014;9(4):e95192.
   PubMed Web of Science ®Google Scholar
• Mahboob S, Ahn SB, Cheruku HR, et al. A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers. Clin Proteomics. 2015;12(1):10.
   PubMedGoogle Scholar
• Ewaisha R, Meshay I, Resnik J, et al. Programmable protein arrays for immunoprofiling HPV-associated cancers. Proteomics. 2016;16(8):1215–1224.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100(20):1432–1438.
   PubMed Web of Science ®Google Scholar
• De Marco F, Bucaj E, Foppoli C, et al. Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues. Plos One. 2012;7(3):e34366.
   PubMedGoogle Scholar
• Wei L, Wang Z, Cui T, et al. Proteomic analysis of cervical cancer cells treated with adenovirus-mediated MDA-7. Cancer Biol Ther. 2008;7(4):510–516.
   PubMed Web of Science ®Google Scholar